Russian Heart Failure Journal 2013year Markers of cytokine activity and oxidative stress in patients with chronic heart fail


To access this material please log in or register

Register Authorize
2013/№6

Markers of cytokine activity and oxidative stress in patients with chronic heart fail

Drapkina O. M., Palatkina L. O.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: GDF-15, OxyStat, oxidative stress, CHF, cytokines

DOI: 10.18087/rhfj.2013.6.1885

Background. Studying the role of inflammation and oxidative stress (OS) markers in the CHF pathogenesis is very relevant due to CHF high prevalence and social and economy significance. Aim. Evaluating the clinical and diagnostic significance of GDF-15 levels and total levels of organic peroxides (OxyStat) in patients with CHF and justifying the use of these biological markers for diagnostics and evaluation of CHF severity. Materials and methods. The study enrolled 81 patients, including 28 patients with normal LV EF (>50 %) and diastolic dysfunction (CHF-PEF group), 27 patients with reduced LV EF (<50 %) (CHF with reduced EF group), and 26 patients without CHF signs matched by sex and concomitant disease (reference group). GDF-15 levels and total OxyStat concentration in plasma were measured in all patients. Results. Mean GDF-15 and total OxyStat levels were significantly higher in CHF patients than in the reference group. Correlations were found between levels of study markers and clinical, laboratory and instrumental characteristics of CHF. An interrelation was found between GDF-15 levels and the marker of diastolic dysfunction, the Е / А ratio as measured by Doppler echoCG. A direct correlation was found between GDF-15 levels and total OxyStat level. Conclusion. The study has demonstrated that measurement of the cytokine activation, GDF-15 and the OS marker, total peroxide concentration can provide important additional information for evaluation of CHF severity and progression.
  1. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7.
  2. Bleumink GS, Knetsch AM, Sturkenboom MC et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25 (18):1614–1619.
  3. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8 (1):30–41.
  4. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive Summary: Heart Disease and Stroke Statistics 2010 Update: A Report From the American Heart Association. Circulation. 2010;121 (7):948–954.
  5. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распро­страненность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (3):112–115.
  6. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  7. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26 (6):447–462.
  8. Агеев Ф. Т. Эволюция представлений о диастолической функции сердца. Сердечная недостаточность. 2000;1 (2):48–50.
  9. Драпкина О. М., Ашихмин Я. И., Ивашкин В. Т. Сложности клинической диагностики и лечения диастолической хронической сердечной недостаточности у пациентов с артериальной гипертензией. Журнал Сердечная недостаточность. 2009;10 (4) 208–216.
  10. Драпкина О. М., Дуболазова Ю. В. Портрет диастолической сердечной недостаточности. Артериальная гипертензия. 2010;16 (6):613–620.
  11. Castagno D, Jhund PS, McMurray JJ et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail. 2010;12 (6):607–616.
  12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325 (5):293–302.
  13. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342 (8875):821–828.
  14. Беленков Ю. В., Агеев Ф. Т., Мареев В. Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? Сердечная Недостаточность. 2000;1 (4):135–138.
  15. Anker SD, Egerer KR, Volk HD et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 1997;79 (10):1426–1430.
  16. Драпкина О. М., Корнеева О. Н., Палаткина Л. О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические перспективы. Артериальная гипертензия. 2011;17 (13):1–6.
  17. Brown DA, Breit SN, Buring J et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359 (9324):2159–2163.
  18. Kempf T, Björklund E, Olofsson S et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28 (23):2858–2865.
  19. Kempf T, von Haehling S, Peter T et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50 (11):1054–1060.
  20. Wollert K, Kempf T, Lagerqvist B et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116 (14):1540–1548.
  21. Anand I, Kempf T, Rector T et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease seve­rity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122 (14):1387–1395.
  22. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358 (20):2148–2159.
  23. Kempf T, Horn-Wichmann R, Brabant G et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53 (2):284–291.
  24. Stahrenberg R, Edelmann F, Mende M et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12 (12):1309–1316.
  25. Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113 (5):671–678.
  26. Van den Broek SA, Van Veldhuisen DJ, De Graeff PA et al. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;70 (3):359–363.
  27. Keith M, Geranmayegan A, Sole MJ et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31 (6):1352–1356.
  28. Valko M, Morris H, Cronin M. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12 (10):1161–1208.
  29. Foley P, Stegemann B, Ramachandran S et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J. 2009;30 (22):2749–2757.
  30. Van Huyen J, Cheval L, Bloch-Faure M et al. GDF15 triggers homeostatic proliferation of acid-secreting collecting duct cells. J Am Soc Nephrol. 2008;19 (10):1965–1974.
  31. Nishiyama Y, Ikeda H, Haramaki N et al. Oxidative stress is related to exercise intolerance in patients with heart failure. Am Heart J. 1998;135 (1):115–120.
Drapkina O.M., Palatkina L.O. Markers of cytokine activity and oxidative stress in patients with chronic heart fail. Russian Heart Failure Journal. 2013;14 (6):341-346

To access this material please log in or register

Register Authorize
Ru En